Literature DB >> 14501508

Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.

Michael G House1, James G Herman, Ming Zhou Guo, Craig M Hooker, Richard D Schulick, Keith D Lillemoe, John L Cameron, Ralph H Hruban, Anirban Maitra, Charles J Yeo.   

Abstract

OBJECTIVE: Because histologic features can be unreliable in determining the malignant potential of pancreatic endocrine neoplasms (PENs), we characterized the methylation patterns of PENs to develop a molecular marker system useful for clinical prognosis. SUMMARY BACKGROUND DATA: Aberrant promoter methylation of tumor suppressor genes is associated with a loss of gene function that can afford selective growth advantages to neoplastic cells. Gene hypermethylation, coupled with sporadic genetic mutations, defines the heterogeneous biology of human neoplasms.
METHODS: Forty-eight well-differentiated PENs were subjected to methylation-specific polymerase chain reaction to detect aberrant methylation associated with 11 candidate tumor suppressor genes (INK4a/p16, APC, O6-MGMT, hMLH1, p73, E-cadherin, RAR-beta, p14ARF, GST-pi, TIMP3, and RASSF1A). Methylation differences among PENs, subdivided according to tumor size, lymph node status, or liver metastasis, were analyzed, and the association of gene methylation with tumor recurrence and patient survival was evaluated.
RESULTS: Aberrant hypermethylation of any of the 11 tumor suppressor genes was detected in 87% of the PENs. In decreasing order of frequency, the 5 most commonly methylated genes were: RASSF1A (75%), INK4a/p16 (40%), O6-MGMT (40%), RAR-beta (25%), and hMLH1 (23%). In general, tumors larger than 5 cm and those associated with lymph node or hepatic metastases exhibited a higher frequency of methylation at each promoter site compared with PENs without malignant histologic features. The methylation of specific tumor suppressor genes was an independent predictor of early PEN recurrence and decreased 5-year survival following surgical resection. The accumulation of methylation of multiple tumor suppressor genes was associated with early tumor recurrence and reduced survival among a subpopulation of patients with lymph node-negative PENs.
CONCLUSIONS: Aberrant methylation of multiple tumor suppressor genes is associated with advanced tumor stage and identifies molecularly distinct PENs with identical histologic characteristics. The methylation status of specific tumor suppressor genes is predictive of PEN behavior.

Entities:  

Mesh:

Year:  2003        PMID: 14501508      PMCID: PMC1422710          DOI: 10.1097/01.sla.0000086659.49569.9e

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

1.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.

Authors:  P L Jones; G J Veenstra; P A Wade; D Vermaak; S U Kass; N Landsberger; J Strouboulis; A P Wolffe
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

2.  A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications.

Authors:  D C Chung; A P Smith; D N Louis; F Graeme-Cook; A L Warshaw; A Arnold
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

3.  Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.

Authors:  P Muscarella; W S Melvin; W E Fisher; J Foor; E C Ellison; J G Herman; W J Schirmer; C L Hitchcock; B R DeYoung; C M Weghorst
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

4.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

Authors:  S La Rosa; F Sessa; C Capella; C Riva; B E Leone; C Klersy; G Rindi; E Solcia
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

5.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

Review 6.  Alterations in DNA methylation: a fundamental aspect of neoplasia.

Authors:  S B Baylin; J G Herman; J R Graff; P M Vertino; J P Issa
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

7.  Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors.

Authors:  D C Chung; S B Brown; F Graeme-Cook; L G Tillotson; A L Warshaw; R T Jensen; A Arnold
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

Authors:  J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.

Authors:  B M Evers; P L Rady; K Sandoval; I Arany; S K Tyring; R L Sanchez; W H Nealon; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  46 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 2.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

Review 3.  Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Authors:  P Mapelli; E O Aboagye; J Stebbing; R Sharma
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

4.  Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.

Authors:  Carole Vitellius; Caroline Eymerit-Morin; Dominique Luet; Lionel Fizanne; Fanny Foubert; Sandrine Bertrais; Marie-Christine Rousselet; François-Xavier Caroli-Bosc
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 5.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Nuclear receptors and pathogenesis of pancreatic cancer.

Authors:  Simone Polvani; Mirko Tarocchi; Sara Tempesti; Andrea Galli
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 7.  Islet biology, the CDKN2A/B locus and type 2 diabetes risk.

Authors:  Yahui Kong; Rohit B Sharma; Benjamin U Nwosu; Laura C Alonso
Journal:  Diabetologia       Date:  2016-05-07       Impact factor: 10.122

Review 8.  Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Authors:  Michael S Lee; Bert H O'Neil
Journal:  J Gastrointest Oncol       Date:  2016-10

9.  Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

Authors:  Daniela Furlan; Nora Sahnane; Mara Mazzoni; Roberta Pastorino; Ileana Carnevali; Michele Stefanoli; Andrea Ferretti; Anna Maria Chiaravalli; Stefano La Rosa; Carlo Capella
Journal:  Virchows Arch       Date:  2012-12-09       Impact factor: 4.064

10.  Borderline and malignant phyllodes tumors display similar promoter methylation profiles.

Authors:  Jo-Heon Kim; Yoo Duk Choi; Ji Shin Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Min Ho Park; Jung Han Yoon
Journal:  Virchows Arch       Date:  2009-11-19       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.